Antimicrobial utilization and resistance in Pseudomonas aeruginosa using segmented regression analysis: a comparative study between Serbia and eight European Countries
- 7 June 2023
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 45 (4) , 989-998
Abstract
Background In Europe, Serbia occupies a high position in antibiotic utilization and antimicrobial resistance (AMR). Aim The aim was to analyse utilization trends of meropenem, ceftazidime, aminoglycosides, piperacillin/tazobactam and fluoroquinolones (2006–2020), and the reported AMR in Pseudomonas aeruginosa (2013–2020) in Serbia and to compare with data from eight European countries (2015–2020). Method Joinpoint regression was used to analyse antibiotic utilization data (2006–2020) and the reported AMR in Pseudomonas aeruginosa (2013–2020). Data sources were relevant national and international institutions. Antibiotic utilization and AMR in Pseudomonas aeruginosa data in Serbia were compared with eight European countries. Results There was a significantly increased trend for ceftazidime utilization and reported resistance in Pseudomonas aeruginosa, Serbia (p < 0.05) (2018–2020). For ceftazidime, piperacillin/tazobactam, and fluoroquinolones resistances in Pseudomonas aeruginosa an increased trend was observed, Serbia (2013–2020). A decrease in both the utilization of aminoglycosides, Serbia (p < 0.05) (2006–2018) and contemporaneous Pseudomonas aeruginosa resistance (p > 0.05) was detected. Fluoroquinolone utilization (2015–2020) was highest in Serbia compared to Netherlands and Finland, 310 and 305% higher, similar compared to Romania, and 2% less compared to Montenegro. Aminoglycosides (2015–2020) were 2550 and 783% more used in Serbia compared to Finland and Netherlands, and 38% less regarding Montenegro. The highest percentage of Pseudomonas aeruginosa resistance was in Romania and Serbia (2015–2020). Conclusion The use of piperacillin/tazobactam, ceftazidime and fluoroquinolones should be carefully monitored in clinical practice due to increased Pseudomonas aeruginosa resistance. The level of utilization and AMR in Pseudomonas aeruginosa is still high in Serbia compared to other European countries.Keywords
Funding Information
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (451-03-68/2022-14/200161)
This publication has 23 references indexed in Scilit:
- Self-medication with antibiotics in Serbian households: a case for action?International Journal of Clinical Pharmacy, 2017
- Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year studyJournal of Clinical Pharmacy and Therapeutics, 2016
- A time for action: antimicrobial resistance needs global responseBulletin of the World Health Organization, 2016
- Vital Signs: Preventing Antibiotic‐Resistant Infections in Hospitals — United States, 2014American Journal of Transplantation, 2016
- Retrospective analysis of nosocomial infections in an Italian tertiary care hospital.2016
- The New and Old Europe: East-West Split in Pharmaceutical SpendingFrontiers in Pharmacology, 2016
- Home pharmacies in Serbia: an insight into self-medication practiceInternational Journal of Clinical Pharmacy, 2015
- Self-Medication Practices and Risk Factors for Self-Medication among Medical Students in Belgrade, SerbiaPLOS ONE, 2014
- Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, IndiaJournal of Antimicrobial Chemotherapy, 2011
- Permutation tests for joinpoint regression with applications to cancer ratesStatistics in Medicine, 2000